CJC 1295 NO DAC (10mg)

CJC-1295 No DAC is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates pulsatile growth hormone secretion without the extended half-life modification of DAC.

CJC-1295 No DAC is a 29-amino-acid analog of GHRH designed to bind to receptors on the anterior pituitary gland, triggering the release of endogenous growth hormone (GH) in a pulsatile manner, closely mimicking the body’s natural GH secretion patterns www.realpeptides.co+1. Unlike CJC-1295 DAC, it lacks the Drug Affinity Complex (DAC), meaning it does not bind to albumin in the bloodstream and therefore has a short half-life of approximately 30 minutes peptidedeck.com+2. This rapid clearance allows for precise temporal control over GH release, which is particularly useful in research settings or protocols requiring short-term stimulation www.realpeptides.co.

Mechanism of Action

CJC-1295 No DAC functions as a GHRH receptor agonist, binding to somatotroph cells in the pituitary and initiating intracellular signaling cascades that result in GH synthesis and secretion www.realpeptides.co. It includes amino acid substitutions that increase stability against enzymatic degradation, specifically by dipeptidyl peptidase-4, which normally breaks down natural GHRH www.realpeptides.co. The peptide’s action amplifies natural GH pulses without bypassing the body’s regulatory feedback mechanisms, such as somatostatin inhibition and IGF-1 negative feedback peptidedeck.com+1.

Key Differences from CJC-1295 DAC

• Half-life: No DAC lasts about 30 minutes, whereas DAC-modified CJC-1295 can remain active for 6–8 days due to albumin binding peptidedeck.com+1.
• GH release pattern: No DAC produces short, pulsatile GH spikes, while DAC provides sustained GH elevation peptidedeck.com+1.
• Dosing frequency: No DAC typically requires 1–2 daily injections, whereas DAC can be administered once or twice per week peptidedeck.com+1.
• Research applications: No DAC is preferred when precise temporal control of GH signaling is needed, allowing studies of acute GH dynamics without prolonged systemic exposure www.realpeptides.co.

Applications

CJC-1295 No DAC is NOT FDA APPROVED and primarily used in research and experimental protocols to study growth hormone physiology, tissue repair, muscle growth, and metabolic effects. Its short-acting nature makes it ideal for investigating pulsatile GH responses and for protocols where sustained GH elevation is not desired www.realpeptides.co+1.
In summary, CJC-1295 No DAC is a short-acting, unmodified GHRH analog that stimulates natural GH release in pulses, offering precise control over growth hormone dynamics, in contrast to the long-acting DAC-modified version which provides sustained GH elevation peptidedeck.com+2.